Application of Stem Cell Therapy in Myelofibrosis

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm.
• Allogeneic hematopoietic stem cell transplantation (HCT) is the only curative option for MF.
• HCT involves significant risks, necessitating careful patient selection.

Purpose of the Study:

• To review recent advancements in HCT for MF.
• To focus on improved risk stratification for HCT in MF patients.
• To discuss the optimal timing of HCT in the context of JAK inhibitor therapy.

Main Methods:

• Review of recent literature on HCT for myelofibrosis.
• Analysis of risk stratification models for MF patients undergoing HCT.
• Discussion of treatment paradigms considering JAK inhibitors and HCT timing.

Main Results:

• Risk stratification is essential for selecting appropriate candidates for HCT.
• The advent of JAK inhibitors complicates the decision-making process for HCT timing.
• Careful consideration of disease risk, patient fitness, and transplant factors is paramount.

Conclusions:

• Optimizing patient selection and timing are critical for improving HCT outcomes in MF.
• Further research is needed to refine HCT protocols in the evolving MF treatment landscape.
• Balancing the risks and benefits of HCT with emerging therapies is key for MF management.